Intermolecular (NASDAQ:IMI) Receiving Positive Press Coverage, Study Shows

News articles about Intermolecular (NASDAQ:IMI) have trended positive on Sunday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Intermolecular earned a daily sentiment score of 0.26 on Accern’s scale. Accern also assigned media headlines about the semiconductor company an impact score of 44.9733409601333 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Separately, ValuEngine upgraded Intermolecular from a “sell” rating to a “hold” rating in a report on Sunday, December 31st.

Shares of Intermolecular (NASDAQ IMI) opened at $1.34 on Friday. Intermolecular has a 12-month low of $0.80 and a 12-month high of $1.65. The company has a market capitalization of $66.41, a price-to-earnings ratio of -4.96 and a beta of 1.15.

TRADEMARK VIOLATION WARNING: “Intermolecular (NASDAQ:IMI) Receiving Positive Press Coverage, Study Shows” was first reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at

Intermolecular Company Profile

Intermolecular, Inc provides thin film solutions. The Company’s high productivity combinatorial (HPC) platform, which consists of its tempus processing tools, its automated characterization methods, and its Informatics analysis software, is purpose-built for research and development (R&D) using combinatorial process systems.

Insider Buying and Selling by Quarter for Intermolecular (NASDAQ:IMI)

Receive News & Ratings for Intermolecular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intermolecular and related companies with's FREE daily email newsletter.

Leave a Reply